Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(7):471-472; doi:10.1093/jnci/dji100
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chlebowski, R. T.
Right arrow Articles by Anderson, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chlebowski, R. T.
Right arrow Articles by Anderson, G. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

EDITORIAL

Progestins and Recurrence in Breast Cancer Survivors

Rowan T. Chlebowski, Garnet L. Anderson

Affiliations of authors: Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, Torrance, CA (RTC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (GLA)

Correspondence to: Rowan T. Chlebowski, MD, PhD, Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center, 1124 W. Carson St., Bldg. J-3, Torrance, CA 90502 (e-mail: rchlebow@whi.org).

The first 10% of the full text of this article appears below.

Menopausal hormone therapy use in breast cancer survivors is controversial, and clinical trials of this issue have proven difficult. Eight years ago, two separate randomized trials of this question were begun, but accrual difficulties led to development of a merger with a joint analysis plans. In 2004 the trials were stopped early after an interim combined analysis of the pooled data found an increased risk for breast cancer recurrence in the hormone group (hazard ratio [HR] = 1.8, 95% confidence interval [CI] = 1.03 to 3.1) relative to the control group. One study, the Hormone Replacement Therapy After Breast Cancer—Is It Safe (HABITS), then reported substantially increased breast cancer recurrences with hormone use (HR = 3.3, 95% CI = 1.5 to 7.4). However, risk of breast cancer recurrence in this comparison in the Stockholm trial was lower (HR = 0.8, 95% CI = 0.4 to 1.9), with statistically significant . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
R. T. Chlebowski and R. L. Prentice
Menopausal Hormone Therapy in BRCA1 Mutation Carriers: Uncertainty and Caution
J Natl Cancer Inst, October 1, 2008; 100(19): 1341 - 1343.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
C. Duffy, K. Perez, and A. Partridge
Implications of Phytoestrogen Intake for Breast Cancer
CA Cancer J Clin, September 1, 2007; 57(5): 260 - 277.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Schumacher, R. Guennoun, A. Ghoumari, C. Massaad, F. Robert, M. El-Etr, Y. Akwa, K. Rajkowski, and E.-E. Baulieu
Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System
Endocr. Rev., June 1, 2007; 28(4): 387 - 439.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. L. Loprinzi, R. Levitt, D. Barton, J. A. Sloan, S. R. Dakhil, D. A. Nikcevich, J. D. Bearden III, J. A. Mailliard, L. K. Tschetter, T. R. Fitch, et al.
Phase III Comparison of Depomedroxyprogesterone Acetate to Venlafaxine for Managing Hot Flashes: North Central Cancer Treatment Group Trial N99C7
J. Clin. Oncol., March 20, 2006; 24(9): 1409 - 1414.
[Abstract] [Full Text] [PDF]